Advertisement

Topics

Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole

2014-08-27 03:12:11 | BioPortfolio

Summary

The investigators propose the evaluation of posaconazole and benznidazole in humans for the treatment of Chagas disease chronical infection. Exploratory trial of posaconazole antiparasitic activity against Trypanosoma cruzi.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Chagas Disease

Intervention

Benznidazole, Posaconazole

Location

International Health Unit Metropolitana Nord
Santa Coloma
Barcelona
Spain

Status

Not yet recruiting

Source

Hospital Universitari Vall d'Hebron Research Institute

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:12:11-0400

Clinical Trials [75 Associated Clinical Trials listed on BioPortfolio]

The BENEFIT Trial: Evaluation of the Use of an Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease

The purpose of this study is to determine if 60 days of treatment with an antiparasitic drug (benznidazole) could prevent the progression of cardiac disease in patients with Chagas disease...

Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.

A phase 2 clinical trial to evaluate the the efficacy of different benznidazole regimens (300mg/day for 60 days, 150mg/day for 60 days, and 400mg/day for 15 days) for the treatment of chro...

Pharmacokinetic Drug-Drug Interaction Study

The purpose of this study is to determine whether benznidazole and E1224 should be administered concomitantly in patients with Chagas Disease as not enough data are available. This study a...

BENDITA BEnznidazole New Doses Improved Treatment and Associations

Recent scientific advances have provided further impetus to develop new therapeutic approaches for Chagas Disease (CD) using different doses and duration of BZN, as well as combinations di...

Benznidazole Absorption, Metabolism and Excretion Study

This Phase I ADME study will be conducted to evaluate the pharmacokinetics of benznidazole.

PubMed Articles [14709 Associated PubMed Articles listed on BioPortfolio]

Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study.

The effectiveness of anti-parasite treatment with benznidazole in the chronic Chagas disease (ChD) remains uncertain. We evaluated, using data from the NIH-sponsored SaMi-Trop prospective cohort study...

Simultaneous Quantification of Benznidazole and Posaconazole by HPLC-DAD Using QbD Approach.

To develop an analytical method to simultaneous quantification of benznidazole (BNZ) and posaconazole (POS) by high-performance liquid chromatography with diode-array detection (HPLC-DAD) using design...

The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole.

Chagas disease is still prevalent in rural areas of South America. In endemic areas of Bolivia, school children are screened for the program of Chagas disease eradication of the Ministry of Health, an...

Correction: The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole.

[This corrects the article DOI: 10.1371/journal.pone.0212593.].

Prevalence of Chagas disease in Colombia: A systematic review and meta-analysis.

Despite the adoption of campaigns to interrupt the main vector and to detect Trypanosoma cruzi in blood banks, millions of people are still chronically infected; however, the prevalence data are limit...

Medical and Biotech [MESH] Definitions

A disease of the CARDIAC MUSCLE developed subsequent to the initial protozoan infection by TRYPANOSOMA CRUZI. After infection, less than 10% develop acute illness such as MYOCARDITIS (mostly in children). The disease then enters a latent phase without clinical symptoms until about 20 years later. Myocardial symptoms of advanced CHAGAS DISEASE include conduction defects (HEART BLOCK) and CARDIOMEGALY.

Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.

A nitrovinyl furan used as a schistosomicidal agent and proposed for trypanosomiasis, especially Chagas disease.

The agent of South American trypanosomiasis or CHAGAS DISEASE. Its vertebrate hosts are man and various domestic and wild animals. Insects of several species are vectors.

A subfamily of assassin bugs (REDUVIIDAE) that are obligate blood-suckers of vertebrates. Included are the genera TRIATOMA; RHODNIUS; and PANSTRONGYLUS, which are vectors of TRYPANOSOMA CRUZI, the agent of CHAGAS DISEASE in humans.

More From BioPortfolio on "Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Searches Linking to this Trial